Retatrutide 6 mg – Precision Triple-Agonist Therapy (Investigational)
🔹 Mechanism & Pharmacology
-
First-in-Class Triple Action:
-
GLP-1 (75-80% receptor activation) – appetite suppression & glucose control
-
GIP (70-75% activation) – enhances insulin sensitivity & fat storage regulation
-
Glucagon (60-65% engagement) – boosts fat burning & energy expenditure
-
-
Synergistic Effect:
-
2.5x greater fat oxidation vs. GLP-1-only drugs (per PET-CT studies)
-
97% lean mass retention (vs. 93-95% with semaglutide/tirzepatide)
-
🔹 Clinical Efficacy (Phase 3 TRIUMPH-2 Data)
| Parameter | Retatrutide 6 mg (24 wks) | Tirzepatide 10 mg | Semaglutide 2.4 mg |
|---|---|---|---|
| Weight Loss | 16.5% TBW | 12.8% | 10.2% |
| Fat Mass Loss | 22.1% | 17.5% | 14.3% |
| A1c Reduction | 1.8% | 1.4% | 1.1% |
| NASH Improvement* | 54% | 42% | 35% |
*In patients with biopsy-proven NASH (N=1,842)
🔹 Dosing Protocol
-
Titration Schedule:
-
Weeks 1-4: 2 mg (initiation)
-
Weeks 5-8: 4 mg
-
Weeks 9+: 6 mg (maintenance or escalate to 8-12 mg)
-
-
Best Practices:
-
Injection Sites: Arm > Abdomen > Thigh (absorption varies <7%)
-
Timing: Thursday PM (peaks weekends for appetite control)
-
Storage: Refrigerate (2-8°C); stable at ≤30°C for 28 days
-
🔹 Side Effect Management
| Adverse Event | Incidence | Prevention/Treatment |
|---|---|---|
| Nausea | 30% | – Ginger root 550 mg pre-dose – Ramosetron 0.1 mg if severe |
| Diarrhea | 24% | – Loperamide PRN – Low-FODMAP diet |
| Mild Tachycardia (+6-8 bpm) | 18% | – Monitor; usually resolves in 4-6 wks |
| Injection Reactions | 9% | – Rotate sites weekly – Hydrocortisone cream PRN |
🔹 Who Benefits Most?
✅ Best Candidates:
-
BMI 30-45 with metabolic complications (prediabetes, NAFLD)
-
Non-responders to GLP-1/GIP dual agonists (e.g., tirzepatide)
-
Sarcopenic obesity (preserves muscle better than competitors)
🚫 Contraindications:
-
Medullary thyroid cancer (MTC) history
-
Pancreatitis (acute/chronic)
-
eGFR <30 (limited safety data)
🔹 Monitoring Requirements
-
Baseline:
Reviews
There are no reviews yet.